iiinova — where your digital self keeps evolving

Steven Artandi @stevenartandi.bsky.social · 25/08/2025

SCI member Lawrence Recht & others found that in IDH-mutant gliomas, adjuvant radiation (aXRT) given within 3 months of diagnosis did not improve survival compared to deferred radiation (dXRT). pubmed.ncbi.nlm.nih.gov/40513058/

180

Steven Artandi @stevenartandi.bsky.social · 22/08/2025

SCI member @lindakachuri.bsky.social and colleagues show that adding #polygenic risk scores to multimodal classifiers improves molecular subtyping before surgery. The approach enhanced prediction of isocitrate dehydrogenase mutation status in #glioma patients. www.nature.com/articles/s41...

090

Steven Artandi @stevenartandi.bsky.social · 20/08/2025

SCI member Ovijit Chaudhuri and colleagues found that matrix stiffness and stress relaxation mediate monocyte migration, revealing how monocytes use actin-driven pushing forces at the leading edge to create migration paths in confining viscoelastic matrices. www.pnas.org/doi/10.1073/...

150

Steven Artandi @stevenartandi.bsky.social · 18/08/2025

SCI member Erinn Rankin & others show FTO, an RNA demethylase, drives glutamine reprogramming in #ccRCC, promoting growth. Inhibiting FTO disrupts metabolism, > DNA damage, and reduces survival, but pyrimidines/antioxidants rescue, highlighting FTO as a target. pubmed.ncbi.nlm.nih.gov/40532011/

140

Steven Artandi @stevenartandi.bsky.social · 15/08/2025

SCI member Robert West & others found #DCIS comprises multiple genetic clones with significant phenotypic diversity and linked alterations in epithelial cell states and basement membrane integrity with invasive breast cancer progression. aacrjournals.org/cancerres/ar...

130

Steven Artandi @stevenartandi.bsky.social · 13/08/2025

SCI members and others found radiotherapy increases immunosuppressive VISTA+ myeloid cells in head and neck cancer's microenvironment. VISTA blockade boosts #radiotherapy efficacy by promoting antitumor myeloid activity and T cell responses in multiple cancer models. www.cell.com/cell-reports...

010

Steven Artandi @stevenartandi.bsky.social · 11/08/2025

SCI members found GPT-RadPlan, an AI-driven treatment planning framework, outperformed or matched human experts in prostate and head & neck cancer plans, improving target coverage and reducing organ-at-risk doses by 5 Gy, all with no extra training required. iopscience.iop.org/article/10.1...

100

Steven Artandi @stevenartandi.bsky.social · 08/08/2025

Gao lab created an ML-guided workflow to deimmunize human protein domains for safer #GeneTherapy. They built zinc fingers and drug-controllable transcription factors to target genes like UTRN and SCN1A. www.sciencedirect.com/science/arti... @synbiogaolab.bsky.social‬ #AIandCancer

020

Steven Artandi @stevenartandi.bsky.social · 06/08/2025

SCI member Claudia Petritsch & others found that immune checkpoint blockade, typically ineffective on its own in high-grade #glioma, can become a powerful treatment when combined with BRAF/MEK inhibition in BRAFV600E-mutant high-grade glioma. www.cell.com/cell-reports...

110

Steven Artandi @stevenartandi.bsky.social · 01/08/2025

I am proud to share that U.S. News & World Report has ranked @StanfordHealth among the top ten #CancerHospitals in the nation. This ranking reflects our team's commitment to excellence across research, clinical innovation, and #PatientCare. med.stanford.edu/cancer/about... @usnews.com #CancerCare

130

Steven Artandi @stevenartandi.bsky.social · 31/07/2025

SCI member Haruka Itakura and others developed an MRI-based model to predict survival risk in #TNBC patients, identifying high-risk groups with a 25% 5-year survival gap using a 50-gene signature. The tool showed strong accuracy and clinical potential. www.nature.com/articles/s41...

000

Steven Artandi @stevenartandi.bsky.social · 30/07/2025

SCI member Edward Graves & others developed a method to enhance the effectiveness of hypoxia-targeted drugs in solid tumors.

researchgate.net

000

Steven Artandi @stevenartandi.bsky.social · 28/07/2025

SCI member Edgar Engleman & team found tumors use erythropoietin (EPO) to block immune attack. In #LiverCancer models, tumor EPO reprograms macrophages via EPOR to create a T cell-poor environment. Blocking the EPO/EPOR axis reactivates immunity & shrinks tumors. pubmed.ncbi.nlm.nih.gov/40273234/

000

Steven Artandi @stevenartandi.bsky.social · 25/07/2025

SCI member Allison Kurian & others found that nearly half of #BreastCancer patients continue endocrine therapy beyond 5 years. The study emphasizes the importance of shared decision-making. academic.oup.com/jnci/advance...

000

Steven Artandi @stevenartandi.bsky.social · 23/07/2025

Alexa Pohl & others found that transportation insecurity negatively impacted #BreastaCancerScreening, while social support positively affected colorectal and #BreastCancer screening. No interaction was found between social support and transportation insecurity. jamanetwork.com/journals/jam...

010

Steven Artandi @stevenartandi.bsky.social · 23/07/2025

By uniting the innovative research efforts of Stanford Medicine and UCSF and drawing from the lessons of past successes, we can propel toward a future where cancer is no longer a formidable foe. @stanfordmedicine.bsky.social @ucsfcancer.bsky.social

130

Steven Artandi @stevenartandi.bsky.social · 21/07/2025

Stanford postdoc Minji Jung & SCI members found #KidneyCancer survivors had a higher rate of depression and anxiety, especially during the early phase following diagnosis, compared with the noncancer population. aacrjournals.org/cebp/article...

010

Steven Artandi @stevenartandi.bsky.social · 14/07/2025

Post doc @jkim-1003.bsky.social & others found #AI natural language processing–enabled analysis of patient messages can generate valuable research topics that prioritize patient perspectives in #CancerCare, guiding future patient-centered health research. jamanetwork.com/journals/jam...

011

Steven Artandi @stevenartandi.bsky.social · 11/07/2025

SCI member Sydney Lu & others found mutations in RNA splicing factors drive mis-spliced mRNA isoforms in cancers. They identified neoantigens from splicing alterations in #leukemia, showing TCR-engineered T cells target these mutations. pubmed.ncbi.nlm.nih.gov/40273911/

000

Steven Artandi @stevenartandi.bsky.social · 09/07/2025

SCI member @johnleppert.bsky.social‬ & others review the challenge of managing small renal masses, urging caution over reflexive treatment. Drawing lessons from low-risk #ProstateCancer, they propose the TOP model to reduce overtreatment. pubmed.ncbi.nlm.nih.gov/40447472/

010

Steven Artandi @stevenartandi.bsky.social · 07/07/2025

SCI member Paul Mischel & others found that #ecDNA drives evolution & heterogeneity in urothelial carcinoma, playing an early role in tumorigenesis. The study highlights immune evasion mechanisms linked to ecDNA, offering insights for developing targeted therapies. pubmed.ncbi.nlm.nih.gov/40331621/

010

Steven Artandi @stevenartandi.bsky.social · 03/07/2025

Saurabh Dahiya showed 87% response and 78% complete remission in hard-to-treat #LBCL with low severe side effects. Early ASCO 2025 data suggest dual CD19/CD20 CAR-T could be a powerful new option. www.cgtlive.com/view/cd19-20... #ASCO25

cgtlive.com

CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL

KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.

000

Steven Artandi @stevenartandi.bsky.social · 30/06/2025

SCI member Seung Kim & others found that stromal KITL in the pancreas restrains tumor progression. Downregulation of KITL during tumorigenesis promotes cancer. KITL signaling may offer potential for cancer prevention without disrupting tissue homeostasis. pubmed.ncbi.nlm.nih.gov/39918337/

000

Steven Artandi @stevenartandi.bsky.social · 27/06/2025

SCI member Joel Neal & others found mobocertinib is not superior to platinum-based chemotherapy in treating EGFR ex20ins+ advanced/metastatic #NSCLC. No significant difference in progression-free survival, but mobocertinib showed longer response duration. pubmed.ncbi.nlm.nih.gov/39879577/

000

Steven Artandi @stevenartandi.bsky.social · 25/06/2025

SCI member David Miklos & others report that allogeneic CD19 # CAR-T cells show 58% overall response and 42% complete response in CD19 CAR T-naïve patients with relapsed/refractory LBCL, with a manageable safety profile. pubmed.ncbi.nlm.nih.gov/39946666/ #LBCL"

010

Steven Artandi @stevenartandi.bsky.social · 23/06/2025

Zhengyi Deng & others found excess weight and adult weight gain were associated with increased risk of #RenalCellCarcinoma (RCC), particularly ccRCC, whereas weight loss was associated with reduced risk. acsjournals.onlinelibrary.wiley.com/doi/abs/10.1...

010

Steven Artandi @stevenartandi.bsky.social · 20/06/2025

SCI members Michael Longaker, Tushar Desai, Howard Chang, & others establish an atlas of pro- and anti-fibrotic factors that underlie lung matrix architecture and implicate fibroblast-associated biological features in modulating #fibrotic progression vs resolution. www.nature.com/articles/s41...

000

Steven Artandi @stevenartandi.bsky.social · 18/06/2025

SCI member Irv Weissman & team introduce an engineered #macrophage approach for cancer therapy. Using eSPR tech, macrophages target tumor heterogeneity, resist polarization, & enhance CD8 T-cell responses. Suggests potential for improved #CancerImmunotherapy. pubmed.ncbi.nlm.nih.gov/40307254/

020

Steven Artandi @stevenartandi.bsky.social · 13/06/2025

Stanford's Emma Lundberg & others create a global map of human subcellular architecture, revealing 275 molecular assemblies & unexpected roles for 975 proteins. Key discoveries include novel cancer proteins & insights into RNA processing & immune signaling. www.nature.com/articles/s41...

012

Steven Artandi @stevenartandi.bsky.social · 11/06/2025

This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. We’re proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social

041

Steven Artandi @stevenartandi.bsky.social · 09/06/2025

SCI members Julia Ransohoff & Allison Kurian & others found that most women with #BreastCancer who paused endocrine therapy for pregnancy did not restart treatment after having a child.

jamanetwork.com

000

Steven Artandi @stevenartandi.bsky.social · 06/06/2025

SCI members Kara Davis & others reveal that low IKAROS levels in B-ALL cells predict antigen escape after #CAR_T therapy. IKAROS^low cells lose B-cell identity, reducing CD19/CD22 expression and increasing therapy resistance. IKAROS may be key to preventing relapse. www.nature.com/articles/s41...

000

Steven Artandi @stevenartandi.bsky.social · 04/06/2025

SCI member Robert Huang & others found major differences in #ColorectalCancer mortality among Asian American subgroups. Asian Indian Americans had the lowest rates; Korean Americans had the highest. Disaggregation by subgroup is essential for understanding risk.

aacrjournals.org

000

Steven Artandi @stevenartandi.bsky.social · 30/05/2025

James Dickerson & others found current pricing makes trastuzumab deruxtecan not cost-effective for #HER2-low #MetastaticBreastCancer. A 41% price cut is needed for value-based care. Best sequencing? Use one antibody-drug conjugate—not both. ascopubs.org/doi/10.1200/... #BreastCancer

ascopubs.org

000

Steven Artandi @stevenartandi.bsky.social · 28/05/2025

SCI leader @funchainmd.bsky.social & others review treatment strategies for #MetastaticMelanoma: BRAF/MEK inhibitors improve survival; #TILtherapy shows 30% durable response; novel TCR-T & CD3 bispecifics emerging; ICI viable even with irAEs, age, or transplant history.

ascopubs.org

010

Steven Artandi @stevenartandi.bsky.social · 23/05/2025

SCI member @everettmoding.bsky.social & others demonstrate that radiation therapy exerts selective pressures on undifferentiated pleomorphic sarcomas and suggest that targeting radioresistant subclonal populations could improve outcomes after radiotherapy. aacrjournals.org/cancerres/ar...

011

Steven Artandi @stevenartandi.bsky.social · 21/05/2025

SCI member Allison Kurian found most lifestyle and reproductive factors don’t substantially raise # BreastCancer risk in BRCA1/2, ATM, CHEK2, or PALB2 mutation carriers—except possibly #HormoneTherapy, which may increase risk for ATM/CHEK2 carriers. aacrjournals.org/cancerrescom...

022

Steven Artandi @stevenartandi.bsky.social · 19/05/2025

Bonnie Halpern-Felsher has received the 2025 John Slade Award from the Society for Research on Nicotine and Tobacco, honoring major contributions to public health and tobacco control through science-based policy and advocacy.

med.stanford.edu

Bonnie Halpern-Felsher, PhD

The Marron and Mary Elizabeth Kendrick Professor in Pediatrics II has been named the recipient of the 2025 John Slade Award by the Society for Research on Nicotine and Tobacco. The award honors…

010

Steven Artandi @stevenartandi.bsky.social · 16/05/2025

Stanford's Lundberg lab & others used advanced imaging and AI tools to uncover hundreds of previously unknown protein functions and identified key cellular assemblies tied to #ChildhoodCancers. www.nature.com/articles/s41...

000

Steven Artandi @stevenartandi.bsky.social · 14/05/2025

SCI member Sumit Shah & others authored new NCCN Guidelines for #TesticularCancer, which provide recommendations for multidisciplinary diagnostics workup, treatment, and follow-up for #TesticularGermCell tumors, including both #seminoma and #nonseminoma. pubmed.ncbi.nlm.nih.gov/40203876/

000

Steven Artandi @stevenartandi.bsky.social · 09/05/2025

SCI member Lidia Schapira cautions against overtreatment, explaining that more treatment and higher doses are not always better. ajmc.com/view/more-is... #CancerTreatment

000

Steven Artandi @stevenartandi.bsky.social · 07/05/2025

acsjournals.onlinelibrary.wiley.com

000

Steven Artandi @stevenartandi.bsky.social · 05/05/2025

I am pleased to announce that Michael Kenney will serve as the next Assistant Dean and Deputy Director of Administration of the SCI. We look forward to his contributions to strengthening the SCI’s research administration and supporting our continued growth and excellence.

000

Steven Artandi @stevenartandi.bsky.social · 02/05/2025

SCI member Ruijiang Li & others found that the pathology foundation model accurately predicts survival outcomes in #GICancers and complements clinicopathologic factors, which may improve risk stratification and guide personalized adjuvant therapy. ascopubs.org/doi/abs/10.1... #AIhealth

ascopubs.org

000

Steven Artandi @stevenartandi.bsky.social · 30/04/2025

SCI member Michelle Chen & others found that the rise and subsequent plateau in the incidence of #ThyroidCancer in the USA since 1975 have been primarily driven by period effects as a result of shifts in clinical practice. www.thelancet.com/journals/lan...

000

Steven Artandi @stevenartandi.bsky.social · 28/04/2025

SCI member James Brooks & others provide a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic #ProstateCancer. aacrjournals.org/clincancerre...

000

Steven Artandi @stevenartandi.bsky.social · 25/04/2025

SCI member Edgar Engleman & others show the EPO/EPOR axis suppresses immunity in HCC by reprogramming macrophages to maintain a T cell–poor TME. Blocking this axis revives immune response, offering a potential therapeutic target for HCC and other tumors. www.science.org/doi/10.1126/... #LiverCancer

060

Steven Artandi @stevenartandi.bsky.social · 23/04/2025

SCI member Sheri Spunt & others found that in a study of 33 pediatric and young adult cancer patients, #RNAsequencing identified potential therapeutic targets for 94% of patients, highlighting RNA sequencing's clinical potential. www.nature.com/articles/s41... #AYACancer #ChildhoodCancer

000